Business Context and Reporting Period
This Form 8-K was filed by Histogenics Corporation (not Ocugen, Inc.) on March 16, 2015. The report discloses the entry into a material definitive agreement and the appointment of a new interim Chief Financial Officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The only financial terms disclosed relate to the new consulting arrangement:
- Compensation: An agreed-upon hourly rate for services plus expense reimbursement.
- Equity Grant: A warrant to purchase up to 7,398 shares of common stock at an exercise price of $9.75 per share.
Material Changes
The primary material change is the departure of Kevin McArdle as Chief Financial Officer, effective March 31, 2015. He is being replaced by Stephen J. DiPalma, Managing Director of Danforth Advisors, LLC, who was appointed as interim CFO effective March 31, 2015.
Outlook, Risks, and Unusual Items
Consulting Agreement Terms:
- Provider: Danforth Advisors, LLC will provide finance, accounting, and administrative functions.
- Term: Initial term of one year, extendable by mutual agreement.
- Termination: 30 days written notice with cause; 60 days written notice without cause.
- Warrant Vesting: Shares vest monthly over two years. Accelerated vesting applies if the agreement is terminated without cause (50% vested if terminated before March 12, 2016; remaining 50% if terminated after).
Management Background: Mr. DiPalma brings over 25 years of experience in life sciences and healthcare, including prior roles as CFO of two public companies and experience with Chapter 11 reorganizations.
Investor Verification Checklist
- Verify the exact hourly rate and expense reimbursement limits in the full Consulting Agreement exhibit.
- Confirm the total potential dilution impact of the 7,398 warrant shares relative to the company's current share count.
- Review the March 6, 2015 Form 8-K for details regarding Kevin McArdle's resignation.
- Monitor the upcoming Form 10-Q for the quarter ending March 31, 2015, for the full text of the exhibits and any updated financial position.